NANT 2004-04: Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma
What is the purpose of this study?
The primary goals of this research study are:
- To determine the maximum tolerated dose of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™LXS) Oral Powder (4-HPR/LXS oral powder) given orally, BID, for seven consecutive days every three weeks, in patients with recurrent and/or resistant neuroblastoma.
- To define the toxicities of 4-HPR/LXS oral powder given on this schedule.
- To determine the plasma pharmacokinetics of 4-HPR given on this schedule.
The secondary goals of this research study are:
- To determine the response rate to 4-HPR/LXS oral powder in patients with recurrent and/or resistant neuroblastoma within the confines of a Phase I study.
- To determine the level of 4-HPR delivered as 4-HPR/LXS oral powder in normal peripheral blood mononuclear cells (PBMC) as a tumor cell surrogate tissue.
Conditions
- Cancer - Neuroblastoma
- Medications
Who should I contact for more information?
Peggy Kaiser, RN, BSN
Cincinnati Children's Hospital Medical Center
Division of Hematology / Oncology
3333 Burnet Ave. Cincinnati, OH 45229-3039
Phone: 513-636-2799
cancer@cchmc.org
Where can I find additional information?
